(NASDAQ: AGIO) Agios Pharmaceuticals's forecast annual revenue growth rate of 82.75% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.38%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.68%.
Agios Pharmaceuticals's revenue in 2025 is $37,035,000.On average, 4 Wall Street analysts forecast AGIO's revenue for 2025 to be $2,334,851,248, with the lowest AGIO revenue forecast at $2,266,800,889, and the highest AGIO revenue forecast at $2,410,430,582. On average, 4 Wall Street analysts forecast AGIO's revenue for 2026 to be $5,679,164,414, with the lowest AGIO revenue forecast at $4,655,802,848, and the highest AGIO revenue forecast at $6,301,173,651.
In 2027, AGIO is forecast to generate $13,904,396,806 in revenue, with the lowest revenue forecast at $9,448,864,717 and the highest revenue forecast at $21,254,878,033.